UroGen PharmaFRA:UR8 +1.20%61 Gross Margin % is 91.88% as of Mar. 2026, which is 3% above its 10-year median of 89.27. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €17.74 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 732 Biotechnology companies, UroGen Pharma ranks better than 84.56% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
UroGen Pharma had a gross margin of 91.88% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
UroGen Pharma Gross Margin % Related Terms
UroGen Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Gross Margin % Comparison
For the Biotechnology subindustry, UroGen Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
UroGen Pharma (FRA:UR8) has a Gross Margin % of 91.88% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on UroGen Pharma and its competitors. This is near median its historical median of 89.27. According to the industry distribution chart, UroGen Pharma ranks #113 out of 732 companies in the Biotechnology industry, placing it in the top 15.4%.
Is UroGen Pharma's Gross Margin % too high?
UroGen Pharma's current Gross Margin % of 91.88% is near median its 10-year median of 89.27. The Biotechnology industry median Gross Margin % is 60.91. UroGen Pharma's value of 91.88% is 50.8% above this industry median. Based on the distribution chart, UroGen Pharma ranks #113 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Gross Margin % compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #113 out of 732 companies for Gross Margin %. This places UroGen Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. UroGen Pharma's value of 91.88% is 50.8% above this benchmark. While the company's 10-year median is 89.27 vs. the industry median of 60.91, UroGen Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Gross Margin % of 91.88% is 50.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Gross Margin % is 91.88%, which is near median its own 10-year median of 89.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.74, compared to a current price of €32.95 — trading 85.7% above its estimated fair value. The current Gross Margin % is 91.88%, which is near median its 10-year median of 89.27 and 50.8% above the Biotechnology industry median of 60.91. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Gross Margin % is 91.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €32.95 is trading 85.7% above its estimated GF Value™ of €17.74.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Gross Margin %: 91.88% (near median its 10-year median of 89.27)
GF Value™: €17.74 vs. price of €32.95 (85.7% above fair value)
Industry Position: 50.8% above the Biotechnology median (#113 of 732)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score
Get the complete analysis for FRA:UR8
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
